Home
Resources
Publications
Comparison of 0.1% Bromfenac Sodium and 0.1% Pemirolast Potassium for the Treatment of Allergic Conjunctivitis

Comparison of 0.1% Bromfenac Sodium and 0.1% Pemirolast Potassium for the Treatment of Allergic Conjunctivitis

Minori Miyake-Kashima, Yoji Takano, Mari Tanaka, Yoshiyuki Satake, Tetsuya Kawakita, Murat Dogru, Naoko Asano-Kato, Kazumi Fukagawa, Hiroshi Fujishima

Jpn J Ophthalmol. Nov-Dec 2004;48(6):587-90.

PMID: 15592786

Abstract:

Purpose:
We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients.
Methods:
Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment.
Results:
Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs.
Conclusion:
Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP100299089	Pemirolast potassium		100299-08-9	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: